Home > Insider Trading > Filing (0001209191-14-008352)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875320	Vertex Pharmaceuticals Inc / Ma	VRTX	Pharmaceutical Preparations (2834)	043039129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1453943	Thomas Connolly	C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210	Svp, Human Resources	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-02-05	11,875	$0.01	15,647	No	4	A	Direct
Common Stock	Acquisiton	2014-02-05	938	$45.11	16,585	No	4	M	Direct
Common Stock	Disposition	2014-02-05	200	$76.82	16,385	No	4	S	Direct
Common Stock	Disposition	2014-02-05	738	$77.83	15,647	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Acquisiton	2014-02-05	62,750	$0.00	62,750	$77.31
Common Stock	Employee Stock Option (right to buy)	Disposition	2014-02-05	938	$0.00	938	$45.11

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
62,750		2024-02-04	No	4	A	Direct
11,250		2023-02-04	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	150	Indirect	401(k)

Footnotes

Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products.
Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $76.82 (range $76.49 to $77.14).
Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $77.83 (range $77.47 to $78.13).
The option vests in 16 quarterly installments from 02/05/2014.
The option vests in 16 quarterly installments from 02/05/2013.